Cardiovascular

Within two decades, MicroPort^® has transformed itself from a market follower, into a global leader in the field of Percutaneous Coronary Intervention (PCI). Its proprietary Firehawk^® targeted eluting stent system, with proven clinical evidence in terms of safety and efficacy, has become a leading stent, setting industry standards for a new generation of global cardiac stents.

MicroPort®’s Vitaflow^® Aortic Valve, uses bovine pericardial leaflets to provide enhanced valve durability, its innovative frame and skirt designs deliver reliable hemodynamic performance, and dependable clinical outcomes for patients. Since launch, MicroPort®’s TAVR solution is fast becoming the leading therapeutic solution to treat aortic valve disease within China, and is currently expanding to more markets across the globe.